6564 Results

People

  1. Gonen
    Gonen
  2. Panageas
    Panageas
  3. Patil
    Patil
  4. Giralt
    Giralt
  5. Zhang
    Zhang
  6. Heller
    Heller
  7. Devlin
    Devlin
  8. Seshan
    Seshan
  9. Jarnagin
    Jarnagin
  10. D'Angelica
    D'Angelica

Groups

  1. Biostatistics Service (6564)
  2. Epidemiology and Biostatistics (6564)
  3. Department of Medicine (3848)
  4. Solid Tumor Oncology Division (2571)
  5. Survivorship Research (2487)
  6. Surgery (2392)
  7. Population Sciences Research Program (2339)
  8. Center for Pancreatic Cancer Research (2080)
  9. GSK Faculty (1977)
  10. Department of Pathology and Laboratory Medicine (1573)
  1. "Biostatistics Service"
Formats
  1. Journal Article (3978)
  2. Meeting Abstract (2394)
  3. Research Letter (51)
  4. Conference Paper (37)
  5. Correspondence (26)
  6. Editorial (25)
  7. Review (21)
  8. Miscellaneous (14)
  9. Book Section (13)
  10. Book Whole (3)
  11. Guidelines (2)
Groups
  1. Biostatistics Service (6564)
  2. Epidemiology and Biostatistics (6564)
  3. Department of Medicine (3848)
  4. Solid Tumor Oncology Division (2571)
  5. Survivorship Research (2487)
  6. Surgery (2392)

More Groups

People
  1. Mithat Gonen (1028)
  2. Sean Devlin (601)
  3. Katherine Panageas (512)
  4. Sujata Patil (511)
  5. Sergio Giralt (464)
  6. Zhigang Zhang (427)

More People

Years
  1. 2025 (118)
  2. 2024 (362)
  3. 2023 (411)
  4. 2022 (407)
  5. 2021 (369)
  6. 2020 (394)

More Years

Publications
  1. Journal of Clinical Oncology (1058)
  2. Blood (432)
  3. Annals of Surgical Oncology (308)
  4. International Journal of Radiation Oncology, Biology, Physics (233)
  5. Clinical Cancer Research (195)
  6. Biology of Blood and Marrow Transplantation (174)

More Publications

Publishers
  1. American Society of Clinical Oncology (1124)
  2. Elsevier Inc. (930)
  3. Springer (625)
  4. American Society of Hematology (486)
  5. American Association for Cancer Research (430)
  6. Nature Publishing Group (311)

More Publishers

Results (6564)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase 2 study of minimal residual disease (MRD)-adapted front line venetoclax and obinutuzumab in fit patients with chronic lymphocytic leukemia (CLL): Effect of obinutuzumab on tumor lysis syndrome (TLS) risk and safety of outpatient venetoclax dose escalation
    Meeting Abstract

    Roeker, L. E.; Zelenetz, A. D.; Park, J. H.; Derkach, A.; Geyer, M. B.; Islam, P.; Falchi, L.; Palomba, M. L.; Kumar, A.; Salles, G.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Impact of response to systemic bridging therapy on clinical outcomes and cytokine profiles in patients receiving CD19-CAR T-cell therapy for B-cell lymphoma
    Meeting Abstract

    Wills, B.; Shouval, R.; Flynn, J. R.; Devlin, S. M.; Parascondola, A.; Saldia, A.; Imber, B. S.; Tomas, A. A.; Landego, I.; Lin, R. J.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Long term follow-up after treatment with allogeneic off-the-shelf CAR T cell therapy for relapsed or refractory B-cell malignancies
    Meeting Abstract

    Shahid, S.; Flynn, G. C.; Mauguen, A.; Bieler, J.; Prockop, S. E.; Scaradavou, A.; Boelens, J. J.; Sauter, C. S.; Perales, M. A.; Giralt, S. A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Evaluation of the impact of tocilizumab use in recipients of CAR T cells for non-Hodgkin lymphoma
    Meeting Abstract

    Cassanello, G.; Luttwak, E.; Devlin, S. M.; Luna De Abia, A.; Corona, M.; Landego, I.; Parascondola, A.; Saldia, A.; Tomas, A. A.; Dahi, P. B.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • A phase 1b multi-center study of the FLT3 inhibitor gilteritinib in combination with the IDH1 inhibitor ivosidenib or the IDH2 inhibitor enasidenib for patients with relapsed or refractory acute myeloid leukemia who have co-occurring FLT3/IDH1 or FLT3/IDH2 mutations
    Meeting Abstract

    Stein, E. M.; Derkach, A.; Melamed, G.; Block, A.; Kim, J.; Georgieva, G.; Thompson, V.; Levine, R. L.; Intlekofer, A. M.; Abdel-Wahab, O.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Pilot study of longitudinal geriatric assessment and neurocognitive evaluation in CAR T-cell therapy for older patients with relapsed refractory, large B-cell lymphoma
    Meeting Abstract

    Lin, R. J.; Kim, S. J.; Correa, D.; Elko, T. A.; Lobaugh, S.; Baser, R.; Koch, A.; Hanley, D. M.; Palomba, M. L.; Dahi, P. B.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRd) and daratumumab, carfilzomib, lenalidomide and dexamethasone (DKRd) as induction therapy in newly diagnosed multiple myeloma
    Meeting Abstract

    Tan, C.; Maclachlan, K. H.; Nemirovsky, D.; Derkach, A.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U. A.; Rajeeve, S.; Patel, D.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • T-cell exhaustion signature predicts early relapse after autologous stem cell transplant for multiple myeloma: BMT CTN 0702 secondary immune analysis
    Meeting Abstract

    Mehanna, N.; Derkach, A.; Gasmi, B.; Anagnostou, T.; Landau, H.; Lahoud, O. B.; Scordo, M.; Shah, G. L.; Hassoun, H.; Maclachlan, K. H.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Gender disparities in allograft access due to HLA-sensitization in multiparous women: Implications for evaluation of female patients for alternative donor transplantation
    Meeting Abstract

    Fingrut, W. B.; Davis, E.; Archer, A.; Brown, S.; Devlin, S. M.; Chinapen, S.; Scaradavou, A.; Politikos, I.; Blouin, A.; Shaffer, B. C.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • CNS radiotherapy as bridging prior to CAR T-cell therapy for non-Hodgkin B-cell lymphoma
    Meeting Abstract

    Cederquist, G.; Schefflein, J.; Devlin, S. M.; Hubbeling, H.; Tringale, K.; Shah, G. L.; Tomas, A. A.; Shouval, R.; Hajj, C.; Fregonese, B.; more...
    Blood (2023)

    Fulltext@MSK | Save